CA2723263A1 - Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides - Google Patents

Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides Download PDF

Info

Publication number
CA2723263A1
CA2723263A1 CA2723263A CA2723263A CA2723263A1 CA 2723263 A1 CA2723263 A1 CA 2723263A1 CA 2723263 A CA2723263 A CA 2723263A CA 2723263 A CA2723263 A CA 2723263A CA 2723263 A1 CA2723263 A1 CA 2723263A1
Authority
CA
Canada
Prior art keywords
compound
oligonucleotide
occurrence
peg
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2723263A
Other languages
English (en)
French (fr)
Inventor
Hong Zhao
Prasanna Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belrose Pharma Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of CA2723263A1 publication Critical patent/CA2723263A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2723263A 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides Abandoned CA2723263A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5586908P 2008-05-23 2008-05-23
US5595008P 2008-05-23 2008-05-23
US61/055,950 2008-05-23
US61/055,869 2008-05-23
US10657608P 2008-10-19 2008-10-19
US10657808P 2008-10-19 2008-10-19
US61/106,576 2008-10-19
US61/106,578 2008-10-19
PCT/US2009/044953 WO2009143412A2 (en) 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides

Publications (1)

Publication Number Publication Date
CA2723263A1 true CA2723263A1 (en) 2009-11-26

Family

ID=41340917

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723263A Abandoned CA2723263A1 (en) 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides

Country Status (6)

Country Link
US (1) US20110105413A1 (https=)
EP (1) EP2288261A4 (https=)
JP (1) JP2011520983A (https=)
CA (1) CA2723263A1 (https=)
TW (1) TW201004648A (https=)
WO (1) WO2009143412A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203066A1 (en) * 2007-08-20 2010-08-12 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties
ITMI20131929A1 (it) * 2013-11-20 2015-05-21 Domenico Terenzio Coniugato dell'acido folico e dell'indolo-3-carbinolo per uso medico
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
MY208384A (en) 2016-03-01 2025-05-05 Ascendis Pharma Bone Diseases As Pth prodrugs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
KR102627405B1 (ko) 2016-09-29 2024-01-18 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
AU2019246390B2 (en) 2018-03-28 2025-03-27 Ascendis Pharma A/S Conjugates
CN111918665B (zh) 2018-03-28 2024-11-26 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
CN112334152A (zh) 2018-05-18 2021-02-05 阿森迪斯药物骨疾病股份有限公司 Pth缀合物的起始剂量
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
WO2020064844A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
AU2020204785A1 (en) 2019-01-04 2021-06-03 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
EP3906065B1 (en) 2019-01-04 2025-04-30 Ascendis Pharma Oncology Division A/S Prr agonist for use in the treatment of cancer
PH12021551591A1 (en) 2019-01-04 2022-04-18 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
MY209748A (en) 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
TW202114660A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 酪胺酸激酶抑制劑結合物
AU2020295725A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Anti-CTLA4 conjugates
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
MX2022007371A (es) 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Tratamiento del hipoparatiroidismo.
EP4146281A1 (en) 2020-05-04 2023-03-15 Ascendis Pharma A/S Hydrogel irradiation
KR20230019889A (ko) 2020-06-03 2023-02-09 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 서열 및 이의 용도
TW202219060A (zh) 2020-08-28 2022-05-16 丹麥商阿森迪斯腫瘤製藥有限公司 醣基化il-2蛋白及其用途
WO2022064035A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
JP2024514095A (ja) 2021-04-01 2024-03-28 アセンディス ファーマ エー／エス 炎症によって誘発される疾患を治療するための長時間作用型成長ホルモンの使用
US20240238325A1 (en) * 2021-04-28 2024-07-18 Japan Science And Technology Agency Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same
IL311539A (en) 2021-09-22 2024-05-01 Ascendis Pharma Bone Diseases As Long-acting pth compound treatments
MX2024006698A (es) 2021-12-13 2024-06-19 Ascendis Pharma Oncology Div A/S Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8).
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
EP4529454A1 (en) 2022-05-23 2025-04-02 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
WO2024184351A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
EP4676535A1 (en) 2023-03-06 2026-01-14 Ascendis Pharma A/S Multi-albumin binding compounds
JP2026509773A (ja) 2023-03-06 2026-03-25 アセンディス ファーマ エー／エス アルブミン結合性部分を含む薬物化合物
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN121175071A (zh) 2023-05-09 2025-12-19 阿森迪斯药物肿瘤股份有限公司 使用il-2缀合物的新型癌症治疗方法
IL326658A (en) 2023-09-04 2026-04-01 Ascendis Pharma Bone Diseases As PTH treatment in chronic kidney disease
WO2026013136A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding compounds
WO2026013135A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding reagents
WO2026013138A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Compounds with improved albumin-binding

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4078032B2 (ja) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
DE60234858D1 (de) * 2001-11-09 2010-02-04 Enzon Inc Polyalkylenoxid-Konjugate von thiolhaltigen Arzneistoffen
KR101207247B1 (ko) * 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
NZ542687A (en) * 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
US7851565B2 (en) * 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
WO2008034123A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
JP2010503708A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
US20100203066A1 (en) * 2007-08-20 2010-08-12 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties

Also Published As

Publication number Publication date
JP2011520983A (ja) 2011-07-21
EP2288261A4 (en) 2013-09-25
TW201004648A (en) 2010-02-01
US20110105413A1 (en) 2011-05-05
WO2009143412A3 (en) 2010-04-15
WO2009143412A2 (en) 2009-11-26
EP2288261A2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
CA2723263A1 (en) Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
JP6522814B2 (ja) オリゴマーおよびオリゴマー・コンジュゲート
KR20090055623A (ko) 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커
US20090202573A1 (en) Polymeric conjugates containing positively-charged moieties
CN102231951A (zh) 用于核酸传递系统的可释放的偶联物
US20100279408A1 (en) Polymeric short interfering rna conjugates
KR20090083334A (ko) 방해된 에스테르 기재 생분해성 링커를 갖는 폴리알킬렌 옥시드
IL293589A (en) Peptide docking vehicle for targeted nucleic acid delivery and uses thereof
EP4509139A1 (en) Conjugate and composition as well as preparation method therefor and use thereof
US8110559B2 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
KR20120044925A (ko) 7-에틸-10-하이드록시캄토테신의 다중-가지 고분자 복합체를 이용한 신생혈관형성 억제 방법
US20250325675A1 (en) Aptamer, conjugate, composition, method for preparing same, and use thereof
CA3246368A1 (en) Aptamer, conjugate, composition, method for preparing same, and use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140522